Susquehanna Fundamental Investments’s Denali Therapeutics DNLI Stock Holding History

Susquehanna Fundamental Investments’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-192,563	Closed	-$3.92M	–	1118
2024 Q4	$3.92M	Buy	+192,563	New	+$4.93M	0.06%	379
2024 Q2	$5.18M	Buy	222,917 +11,900	+6%	+$228K	0.12%	226
2024 Q1	$4.33M	Buy	+211,017	New	+$3.97M	0.2%	138
2023 Q4	–	Sell	-81,308	Closed	-$1.68M	–	145
2023 Q3	$1.68M	Sell	81,308 -9,941	-11%	-$252K	0.11%	156
2023 Q2	$2.69M	Hold	91,249	–	–	0.1%	213
2023 Q1	$2.1M	Hold	91,249	–	–	0.05%	363
2022 Q4	$2.54M	Buy	+91,249	New	+$2.72M	0.04%	428

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Susquehanna Fundamental Investments's DNLI Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 192,563 shares — an estimated $3.92M sold.

Susquehanna Fundamental Investments first reported a position in DNLI in Q4 2022 and held it in 7 quarters. The position peaked at $5.18M in Q2 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

Susquehanna Fundamental Investments reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 192,563 Denali Therapeutics shares in Q1 2025, an estimated $3.92M.
Susquehanna Fundamental Investments first reported a position in Denali Therapeutics in Q4 2022 and held it in 7 quarters.
Susquehanna Fundamental Investments's Denali Therapeutics position peaked at $5.18M in Q2 2024.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.